EirGenix (Taiwan Biotech Co., Ltd.) is officially transitioning to the Taiwan Stock Exchange (TWSE) today (21st). Chairman Dr. Lee-Cheng Liu announced that in addition to the continued momentum of its CDMO business, the company has entered a strategic alliance with TTY Biopharm for the development of ADCs (antibody-drug conjugates) that combine large-molecule biologics with small-molecule drugs. Furthermore, the company’s first biosimilar for breast cancer, EG12014, has already obtained two drug licenses, which are expected to further boost its growth trajectory.
According to statistics, more than 100 biologics are expected to lose patent protection between 2025 and 2035. Healthcare systems in the U.S., Japan, and other countries are in urgent need of biosimilars to ease the strain on medical insurance resources. Regulatory and policy frameworks in the U.S. and Japan are already actively exploring clinical exemptions, accelerated development pathways, and post-market incentive programs.
Currently, fewer than 30 biosimilars are available on the market. Favorable policies and regulatory changes are expected to benefit companies with established biosimilar development technologies, robust manufacturing capacity, and market experience—positioning them as key beneficiaries. This trend will also drive demand for CDMO services, including tech transfers and co-development projects. EirGenix is optimistic about the tremendous business opportunities brought by the patent cliff in biologics and the rise of biosimilars.
Dr. Liu highlighted that EirGenix has accumulated over a decade of expertise in "reverse engineering" and has built a scalable, internationally compliant commercial production facility. Its development pipeline is both focused and diversified. The CDMO business continues to see stable revenue growth, with clients spanning Japan, Europe, the U.S., Asia, and Taiwan. As its biosimilar products reach the market, EirGenix anticipates further expansion and stable growth in profitability.
The company owns its proprietary CHO-K1 cell line and has established capabilities in cell line development, including both mammalian cell cultures and microbial fermentation platforms. Its Zhubei facility is a fully commercialized production base, compliant with cGMP standards, and offers competitive production costs and regulatory expertise in clinical applications and drug approvals worldwide.
EirGenix has formed a strategic ADC alliance with Formosa Laboratories to combine large-molecule and small-molecule drug technologies.
Additionally, EG12014 (a trastuzumab biosimilar), EirGenix’s first biosimilar for breast cancer, has obtained two drug licenses and is marketed in Taiwan under the brand name EIRGASUNR. Its second-generation breast cancer biosimilar, EG1206A (a pertuzumab biosimilar), is currently undergoing a Phase III international multicenter clinical trial. The company is also focusing on subcutaneous (SC) formulation development, with multiple SC pipeline products under continuous development.
Resource: 台康生今轉上市 攜手台耀組ADC聯盟
